Illumina Inc Stock Price, News & Analysis

Illumina (NASDAQ: ILMN) has announced a pilot proteomics program to analyze 50,000 UK Biobank samples in collaboration with multiple partners including deCODE Genetics, Standard BioTools, Tecan, GSK, Johnson & Johnson, and Novartis. The program will utilize Illumina's upcoming Illumina Protein Prep™ solution, which can detect 9,000 unique human proteins.

The first 30,000 samples, funded through coinvestment from Illumina, deCODE Genetics, and Standard BioTools, will be made available to the scientific research community in the second half of 2025. The remaining 20,000 samples will initially be accessible exclusively to industry consortium members before wider release. The project aims to generate high-quality proteomics data to advance biological insights and facilitate biomarker discovery for conditions like cancer and cardiovascular disease.

The Illumina Protein Prep solution, scheduled for launch in first half 2025, is compatible with NovaSeq X, NovaSeq X Plus, and NovaSeq 6000 Systems.

Illumina (NASDAQ:ILMN) has scheduled its fourth quarter and full year 2024 financial results announcement for Thursday, February 6, 2025, after market close. The company will host a conference call at 1:30 pm Pacific Time (4:30 pm Eastern Time) on the same day.

CEO Jacob Thaysen and CFO Ankur Dhingra will lead the conference call to discuss financial and operating results with analysts, investors, and other interested parties. The live webcast will be accessible through Illumina's Investor Info section, with participants advised to join at least ten minutes before the scheduled start time. A replay will be available on the company's website for a minimum of 30 days following the event.

Illumina (NASDAQ: ILMN) has announced significant updates to its NovaSeq X Series, including a new single-flow-cell system, software upgrade v1.3, and new 25B kits. The single-flow-cell system offers the same quality and speed as the NovaSeq X Plus at a more accessible cost for lower-volume labs. The v1.3 software upgrade enhances sequencing performance with improved accuracy and higher yields.

The company began shipping new NovaSeq X 25B 100-cycle and 200-cycle kits in December, optimized for counting applications and assays at scale. Additionally, Illumina launched Single-Cell Prep (formerly Fluent PipSeq V), compatible with NextSeq 1000/2000, NovaSeq 6000, and NovaSeq X platforms. This technology enables scalable experiments from hundreds to millions of cells, offering lower equipment and per-cell costs.

Illumina, a global genomics leader, showcases employee perspectives on working in genomics technology through a video feature. The company highlights how their work impacts global human health through next-generation sequencing solutions across research, clinical, and applied markets. Three Illumina professionals share their experiences and motivations for working at the company, emphasizing their contribution to advancing personalized healthcare. The company's technology supports innovations in various fields, including oncology, reproductive health, genetic disease, microbiology, agriculture, and forensic science.

Ovation.io and Illumina (NASDAQ: ILMN) announced a collaboration to advance precision medicine by combining Illumina's next-generation sequencing platforms with Ovation's 1.6+ million sample biobank. The partnership aims to create comprehensive clinico-genomic datasets for non-oncology indications where current data is insufficient.

The collaboration will initially focus on pilot datasets in liver disease, chronic kidney disease, and GLP-1 receptor agonist treated patients. Building on Ovation's existing IBD Omics product, the partnership will help identify optimal drug targets and biomarkers, potentially reducing development costs and improving treatment success rates. The initiative will leverage de-identified, consented samples linked to longitudinal clinical data, including medical records, laboratory results, and claims.

Illumina has launched the MiSeq i100 and MiSeq i100 Plus Systems, featuring breakthrough room-temperature storage technology for sequencing reagents. Led by Associate Director Erin Imsand, the team developed a lyophilization process that transforms reagents into microspheres, eliminating the need for cold storage and dry ice shipping. The technology incorporates over 140 invention disclosures and 60 patent families.

The innovative process removes water content from materials through sublimation, creating stable, dry microspheres that can be stored at room temperature and rehydrated when needed. This advancement eliminates the need for refrigeration and freezer space, potentially revolutionizing how sequencing reagents are stored and handled in laboratories.

Illumina has demonstrated the effectiveness of Whole-Genome Sequencing (WGS) in blood cancer diagnostics through a comprehensive study. The research evaluated WGS performance in identifying variants specific to Acute Myeloid Leukemia (AML), achieving 100% sensitivity including hard-to-find mutations. The study, conducted at Illumina Laboratory Services, achieved a five-day turnaround time and demonstrated a 95% detection rate at 5% variant allele frequency with 140× coverage.

The company's WGS method utilizes their DRAGEN software and will expand Connected Insights functionality in early 2025 to include automated risk stratification for AML samples. This advancement offers a significant improvement over conventional diagnostic methods, which often require multiple tests and have detection capabilities.

Illumina's DRAGEN Secondary Analysis software has received third-party validation from Baylor College of Medicine, with results published in Nature Biotechnology. The study confirms DRAGEN's superior performance in genome analysis, featuring proprietary algorithms developed in-house. The software includes over a dozen specialized variant callers for challenging genome sections and incorporates a pangenome reference to address Eurocentric bias in genetic data.

The validation demonstrated DRAGEN's exceptional accuracy, with competing tools showing up to 470% more errors. Notably, DRAGEN can process whole human genome analysis in just 30 minutes, compared to several days with other tools. The software's comprehensive approach integrates multiple components efficiently, making it particularly valuable for both individual samples and large-scale population studies.

Illumina (NASDAQ: ILMN) has announced its participation in the upcoming 43rd Annual J.P. Morgan Healthcare Conference. The company's executives will deliver a presentation on January 14, 2024, at 9:00 AM Pacific Time (12:00 PM Eastern Time), followed by a Q&A session at approximately 9:20 AM Pacific Time (12:20 PM Eastern Time).

Investors and interested parties can access the webcast through the Investor Info section on investor.illumina.com. A replay of the presentation will be available on the company's website for a minimum of 30 days after the event.